Related Experiment Video
Updated: Mar 1, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors
Michelle Isaacs1, Katherine T Tonks1,2,3, Jerry R Greenfield1,2,3
1Department of Endocrinology and Diabetes, St Vincent's Hospital, Sydney, New South Wales, Australia.
Abstract:
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are an increasingly prescribed class of medication for type 2 diabetes mellitus. Euglycaemic diabetic ketoacidosis (euDKA) has been reported in association with SGLT2i use. Clinicians need to understand how to recognise and treat this complication. We describe three cases of euDKA in patients treated with SGLT2i.
More Related Videos
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
08:03Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
Published on: June 25, 2017
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Diabetes Mellitus: Type 2 and Gestational
Hypoglycemia and Glucagon
Oral Hypoglycemic Agents: Biguanides and Glitazones